HK1174615A1 - Ghrelin receptor agonist for treatment of dyscrasia - Google Patents

Ghrelin receptor agonist for treatment of dyscrasia

Info

Publication number
HK1174615A1
HK1174615A1 HK13101402.5A HK13101402A HK1174615A1 HK 1174615 A1 HK1174615 A1 HK 1174615A1 HK 13101402 A HK13101402 A HK 13101402A HK 1174615 A1 HK1174615 A1 HK 1174615A1
Authority
HK
Hong Kong
Prior art keywords
dyscrasia
treatment
receptor agonist
ghrelin receptor
ghrelin
Prior art date
Application number
HK13101402.5A
Other languages
English (en)
Chinese (zh)
Inventor
薰 島田
正樹 須藤
多治見　政臣
高橋　伸行
和彥 野野村
Original Assignee
拉誇裏亞創藥株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 拉誇裏亞創藥株式會社 filed Critical 拉誇裏亞創藥株式會社
Publication of HK1174615A1 publication Critical patent/HK1174615A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
HK13101402.5A 2010-02-26 2013-01-31 Ghrelin receptor agonist for treatment of dyscrasia HK1174615A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010043484 2010-02-26
PCT/JP2011/054556 WO2011105611A1 (ja) 2010-02-26 2011-02-28 悪液質を治療するためのグレリン受容体作動物質

Publications (1)

Publication Number Publication Date
HK1174615A1 true HK1174615A1 (en) 2013-06-14

Family

ID=44507004

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13101402.5A HK1174615A1 (en) 2010-02-26 2013-01-31 Ghrelin receptor agonist for treatment of dyscrasia

Country Status (13)

Country Link
US (2) US10975070B2 (xx)
EP (1) EP2540721B1 (xx)
JP (1) JPWO2011105611A1 (xx)
KR (1) KR20120131183A (xx)
CN (1) CN102762564B (xx)
BR (1) BR112012020377B1 (xx)
CA (1) CA2789750C (xx)
ES (1) ES2615731T3 (xx)
FR (1) FR23C1048I1 (xx)
HK (1) HK1174615A1 (xx)
MX (1) MX341660B (xx)
RU (1) RU2012141061A (xx)
WO (1) WO2011105611A1 (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210009438A (ko) * 2012-09-27 2021-01-26 아라타나 세라퓨틱스, 인크. 식욕부진을 조절 화합물 조성물 및 이의 이용 방법
RU2670978C9 (ru) * 2013-05-28 2018-11-22 Раквалиа Фарма Инк. Полиморфные формы
JP2017532350A (ja) * 2014-10-31 2017-11-02 ラクオリア創薬株式会社 グレリン受容体アゴニストとしてのテトラヒドロピラゾロピリジン誘導体
KR20170097212A (ko) * 2015-01-28 2017-08-25 아라타나 세라퓨틱스, 인크. 체중-증량 화합물의 장기 사용을 위한 조성물 및 방법
EP4218757A1 (en) * 2020-09-22 2023-08-02 Kyungpook National University Industry-Academic Cooperation Foundation Use of triazole compound as ghrelin receptor agonist
CN115778960A (zh) * 2022-08-19 2023-03-14 广州六顺生物科技有限公司 一种杂芳环衍生物在制备治疗或预防恶病质药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997984A (en) 1989-12-19 1991-03-05 Shawa Denko K.K. Process for preparation of N-(α-alkoxyethyl)-carboxylic acid amide
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
ATE446758T1 (de) 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
AU2005277389A1 (en) 2004-08-18 2006-03-02 Elixir Pharmaceuticals, Inc. Growth-hormone secretagogues
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
MX2009008561A (es) * 2007-02-13 2010-01-15 Helsinn Therapeutics Us Inc Metodo para tratar trastornos proliferativos celulares utilizando secretagogos.
WO2008153027A1 (ja) 2007-06-11 2008-12-18 Takeda Pharmaceutical Company Limited ピロロキノリン誘導体およびその用途
WO2009063993A1 (ja) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited 縮合ピリジン誘導体およびその用途
WO2009139340A1 (ja) * 2008-05-12 2009-11-19 武田薬品工業株式会社 ピラゾール化合物
KR20210009438A (ko) 2012-09-27 2021-01-26 아라타나 세라퓨틱스, 인크. 식욕부진을 조절 화합물 조성물 및 이의 이용 방법

Also Published As

Publication number Publication date
US10975070B2 (en) 2021-04-13
EP2540721B1 (en) 2016-12-14
MX341660B (es) 2016-08-29
US20210179613A1 (en) 2021-06-17
BR112012020377A8 (pt) 2018-01-02
BR112012020377B1 (pt) 2019-10-08
FR23C1048I1 (fr) 2024-01-19
RU2012141061A (ru) 2014-04-10
CN102762564A (zh) 2012-10-31
JPWO2011105611A1 (ja) 2013-06-20
WO2011105611A1 (ja) 2011-09-01
CA2789750A1 (en) 2011-09-01
EP2540721A1 (en) 2013-01-02
ES2615731T3 (es) 2017-06-08
CN102762564B (zh) 2015-09-30
US20120322821A1 (en) 2012-12-20
EP2540721A4 (en) 2013-08-07
KR20120131183A (ko) 2012-12-04
CA2789750C (en) 2018-03-06
BR112012020377A2 (pt) 2016-05-10
MX2012009774A (es) 2012-10-05

Similar Documents

Publication Publication Date Title
HK1172006A1 (en) Apparatus for hydrogenating biocompatible solution
EP2680853A4 (en) TREATMENT OF CANCER WITH DOPAMINE RECEPTOR ANTAGONISTS
ZA201109334B (en) Dosage forms of apixaban
GB201106527D0 (en) Therapeutic apparatus
EP2603850A4 (en) METHOD FOR AUTHENTICATING PHARMACEUTICAL FORMS
HK1172602A1 (en) Device for selectively hydrogenating biocompatible solution
IL214919A0 (en) Method for therapeutic use
IL215865B (en) Meloxicam formulation
IL222328A (en) Tissue microabulation system
HK1174615A1 (en) Ghrelin receptor agonist for treatment of dyscrasia
GB2497035B (en) Method of authentication
IL224381B (en) Application of b-functionalized dihydroxy-chlorins for pdt
EP2566494A4 (en) CXCR4 RECEPTOR COMPOUNDS
IL225395A0 (en) A mutated androgen receptor antagonist
GB2480740B (en) Apparatus for protecting feet
EP2533780A4 (en) 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA
EP2539706A4 (en) ARYLPIPERAZONE ANTAGONISTS OF OPIOID RECEPTORS
ZA201202379B (en) Antagonists of dsgs2 for treatment of cancer
EP2594275A4 (en) AGENT FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF DIABETES
GB2481022B (en) Anchor apparatus
EP2647632A4 (en) PROCESS FOR PREPARING A MESYLATE OF A-IMATINIB
ZA201102919B (en) Apparatus for placement of stent
TWM401387U (en) Multifunction structure of device for putting on shoes
GB201016519D0 (en) Apparatus for patient adjustment
GB201018113D0 (en) Use of an estrogen receptor ligang for treating disease